DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Clinical trials for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new DLBCL - DIFFUSE LARGE B CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a Chemo-Radiation combo boost CAR t success in tough lymphoma?
Disease control Recruiting nowThis study is for adults with a type of blood cancer called DLBCL that has come back or not responded to treatment. It tests different combinations of chemotherapy and radiation given before standard CAR T cell therapy to see if they can make the treatment work better and be safe…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated May 26, 2026 04:50 UTC
-
New hope for tough lymphomas: experimental drug MDX2003 enters human trials
Disease control Recruiting nowThis study tests a new drug called MDX2003 in adults with several types of B-cell lymphoma (like DLBCL or follicular lymphoma) that have returned or stopped responding to at least two prior treatments. The main goals are to find the safest dose and check if the drug can shrink tu…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: ModeX Therapeutics, An OPKO Health Company • Aim: Disease control
Last updated May 26, 2026 04:48 UTC
-
New cell therapy CT1182 targets tough lymphoma in early trial
Disease control Recruiting nowThis early-phase study tests a new cell therapy called CT1182 in 24 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The main goals are to check safety, find the best dose, and see how well it shrinks tumors. Researchers will monitor side …
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 26, 2026 04:47 UTC
-
Double attack on lymphoma: CAR-T cells followed by antibodies show promise
Disease control Recruiting nowThis study tests whether giving an extra antibody drug (mosunetuzumab or glofitamab) after CAR-T cell therapy can improve results for people with aggressive large B-cell lymphoma that has come back or not responded to prior treatments. About 42 participants will receive the combi…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated May 26, 2026 04:36 UTC
-
New CAR T-Cell therapy targets tough lymphoma cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells. The main…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated May 26, 2026 04:33 UTC
-
New hope for hard-to-treat blood cancer patients in china
Disease control Recruiting nowThis study tests a drug called glofitamab in 20 Chinese adults with a type of blood cancer (diffuse large B-cell lymphoma) that has returned or not responded after at least two prior treatments. The goal is to see if the drug can shrink tumors and improve survival, while monitori…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated May 26, 2026 04:33 UTC
-
Engineered immune cells take on Hard-to-Treat lymphoma
Disease control Recruiting nowThis study tests a new treatment for people with a fast-growing blood cancer called diffuse large B cell lymphoma that has come back or not responded to at least two prior therapies. The treatment uses the patient's own immune cells, which are genetically modified to recognize an…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug combo aims to boost lymphoma remission in patients with key mutations
Disease control Recruiting nowThis study tests whether adding the oral drug zanubrutinib to standard chemotherapy (R-CHOP) helps more people with diffuse large B-cell lymphoma (DLBCL) achieve complete remission. It is for patients whose tumors have certain genetic changes (MYD88, CD79B, NOTCH1 mutations or CD…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New drug cocktail offers hope for Hard-to-Treat lymphoma
Disease control Recruiting nowThis study tests a combination of three drugs (pirtobrutinib, lisaftoclax, and rituximab) in adults with diffuse large B-cell lymphoma that has come back or not responded to at least one prior treatment. The goal is to see if this combo can shrink tumors or make them disappear. A…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New hope for hard-to-treat lymphoma? early trial of LTZ-301 begins
Disease control Recruiting nowThis early-phase study tests a new drug called LTZ-301 in 42 adults with certain types of non-Hodgkin lymphoma that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that …
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: LTZ Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Heart shield for lymphoma patients: new trial aims to stop Chemo's hidden danger
Prevention Recruiting nowThis study tests whether the drug dexrazoxane can prevent heart damage caused by chemotherapy in people with diffuse large B-cell lymphoma (DLBCL). About 324 patients will receive either standard chemo plus dexrazoxane or standard chemo alone. The goal is to see if the drug prote…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Prevention
Last updated May 26, 2026 04:34 UTC
-
New training helps lymphoma doctors have better conversations
Knowledge-focused Recruiting nowThis study tests a new training program called Hematolo-GIST that helps doctors communicate more clearly with patients who have large B-cell lymphoma. The goal is to improve how doctors discuss the diagnosis and plan future care. About 48 people, including doctors and patients, w…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated May 26, 2026 04:38 UTC
-
New spinal fluid test could spot hidden brain cancer spread early
Knowledge-focused Recruiting nowThis study looks at whether a new DNA test on spinal fluid can find signs of lymphoma spreading to the brain before standard tests do. About 50 people with aggressive B-cell lymphoma at high risk for brain relapse will give spinal fluid samples during their first treatment. The g…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated May 19, 2026 12:00 UTC